TY - JOUR
T1 - Postinflammatory hyperpigmentation associated with treatment of solar lentigines using a Q-Switched 532-nm Nd
T2 - YAG laser: a multicenter survey
AU - Kang, Hyun Ji
AU - Na, Jung Im
AU - Lee, Jong Hee
AU - Roh, Mi Ryung
AU - Ko, Joo Yeon
AU - Chang, Sung Eun
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/7/4
Y1 - 2017/7/4
N2 - Purpose: To characterize the risk factors of Korean patients for postinflammatory hyperpigmentation (PIH) during treatment of solar lentigines using a Q-switched 532-nm Nd: YAG (QS 532 NY) laser. Materials and Methods: The present retrospective multicenter study was conducted at the dermatology clinics of five tertiary hospitals in Korea. Between October 2007 and January 2013, 516 patients were enrolled and reviewed for clinical features and factors associated with PIH. Results: The overall incidence of PIH was 20.3%. We demonstrated that patients with erythematous lentigines presented with PIH more frequently compared with those without erythematous lentigines. Among several coexisting conditions, facial diffuse dyschromia was significantly associated with PIH. Furthermore, PIH occurred more frequently in patients with invisible pores and velvety skin. However, age, sex, Fitzpatrick skin’s phototype and season of treatment showed little association with PIH. Conclusions: When a QS 532 NY laser is used to treat individuals with erythematous lentigines, invisible pores and velvety skin, and facial diffuse dyschromia, clinicians should be cautious and consider preventive measures.
AB - Purpose: To characterize the risk factors of Korean patients for postinflammatory hyperpigmentation (PIH) during treatment of solar lentigines using a Q-switched 532-nm Nd: YAG (QS 532 NY) laser. Materials and Methods: The present retrospective multicenter study was conducted at the dermatology clinics of five tertiary hospitals in Korea. Between October 2007 and January 2013, 516 patients were enrolled and reviewed for clinical features and factors associated with PIH. Results: The overall incidence of PIH was 20.3%. We demonstrated that patients with erythematous lentigines presented with PIH more frequently compared with those without erythematous lentigines. Among several coexisting conditions, facial diffuse dyschromia was significantly associated with PIH. Furthermore, PIH occurred more frequently in patients with invisible pores and velvety skin. However, age, sex, Fitzpatrick skin’s phototype and season of treatment showed little association with PIH. Conclusions: When a QS 532 NY laser is used to treat individuals with erythematous lentigines, invisible pores and velvety skin, and facial diffuse dyschromia, clinicians should be cautious and consider preventive measures.
UR - http://www.scopus.com/inward/record.url?scp=84995495552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84995495552&partnerID=8YFLogxK
U2 - 10.1080/09546634.2016.1254330
DO - 10.1080/09546634.2016.1254330
M3 - Article
C2 - 27786580
AN - SCOPUS:84995495552
VL - 28
SP - 447
EP - 451
JO - Journal of Dermatological Treatment
JF - Journal of Dermatological Treatment
SN - 0954-6634
IS - 5
ER -